B-ADENOMA: BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities
Study Details
Study Description
Brief Summary
This study aims to assess the effect, if any, on the adenoma detection rate of BowelScope bowel cancer screening flexible sigmoidoscopies by using the Endocuff Vision device.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Colorectal cancer (CRC) is the fourth most common cancer in the UK with 40,000 new cases diagnosed annually. Most CRCs arise from the adenoma-carcinoma sequence which is a process that can take up to 10 years. Population screening programmes allow for earlier detection and removal of adenomas that may become malignant over time thus reducing CRC mortality. The English Bowel Scope Screening (BSS) programme began in 2013 and invites adults aged 55 and above for a one-off flexible sigmoidoscopy. The aim of the BSS programme is to reduce CRC development via the adenoma-carcinoma sequence through the detection and removal of adenomas from the left side of the colon. A large UK study has shown that offering one-off flexible sigmoidoscopy screening with adenoma clearance to adults aged 55-64 years reduced CRC incidence by 23% and mortality by 31%. Adenoma detection rate (ADR) is the most important marker of mucosal visualisation and is a surrogate marker of high quality colonoscopy. Data from colonoscopy studies have illustrated that a 1% increase in ADR is associated with a 3% decrease in interval colorectal cancer. In the BSS programme, ADR is comparatively lower the that shown in the initial sigmoidoscopy screening trials with a wide variation between endoscopists. Another marker that is often used is adenoma miss rates which also demonstrate a wide variation in clinical practice. Reasons for lesions not being detected at flexible sigmoidoscopy can be extrapolated from colonoscopy data and include; suboptimal technique; shorter withdrawal time; inadequate bowel preparation; presence of flat, depressed or subtle lesions; and the inability to visualise the proximal side of haustral folds, flexures (blind spots) and rectal valves. With the aid of the colonoscopic cuff Endocuff Vision®, the investigators aim to improve visualisation of the colonic mucosa by flattening colonic folds and manipulating them away from the field of forward view the investigators hypothesise that the Endocuff Vision® will improve adenoma detection rates by providing better fold retraction, a wider field of view and better scope tip stabilisation. This clinical randomised study will be conducted in subjects referred and scheduled for screening flexible sigmoidoscopy via the NHS English Bowel Scope Screening (BSS) Programme and will compare Endocuff Vision®-Assisted Flexible Sigmoidoscopy (EAFS) with Standard Flexible Sigmoidoscopy (SFS).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Endocuff-assisted Flexible Sigmoidoscopy Patients in this arm will receive their screening sigmoidoscopy with the Endocuff Vision in situ on the scope |
Device: Endocuff Vision
The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
|
| No Intervention: Standard Flexible Sigmoidoscopy Patients in this arm will receive their screening sigmoidoscopy without the Endocuff on the scope |
Outcome Measures
Primary Outcome Measures
- Adenoma Detection Rate [Day of procedure]
Proportion of examinations expressed as a percentage where at least one adenoma is found
Secondary Outcome Measures
- Mean adenomas detected per procedure [Day of procedure]
Number of adenomas found in each procedure
- Rate of cuff exchange [Day of procedure]
How often the cuff is removed
- Non-inferiority of complete withdrawal time in procedures where no polyps are detected [Day of procedure]
Length of procedure in minutes and seconds
- Compare overall procedure time between groups [Day of procedure]
Length of procedure in minutes and seconds
- Measure differences in ADR accounting for patient procedure based variables (e.g. accounting for extent of examination and bowel preparation). [Day of procedure]
Proportion of examinations expressed as a percentage where at least one adenoma is found
- Compare the rate of discovered cancers between groups [On histology check 48-72 hours post procedure]
Number of cancers found
- Examination extent between groups based on presumed anatomical location with a straight endoscope [Day of procedure]
Anatomical location
- Examination extent between groups based on distance of insertion in centimetres with a straight endoscope [Day of procedure]
Depth of insertion in centimetres
- Patient satisfaction between groups using the Gloucester scale of assessment of patient comfort [Day of procedure]
Numerical 4 point patient comfort score
- Identify any difference in future colonoscopic workload produced by increased ADR in terms of number of patients referred for full colonoscopy between the EAFS and SFS groups. [Day of procedure]
Number of additional colonoscopies required
- Compare the ADR of the first 20% of patients scoped by each colonoscopist with the last 20% of patients in each arm to identify any changes in ADR to assess any learning curve effect. [18 months]
Proportion of examinations expressed as a percentage where at least one adenoma is found
- Compare the baseline ADR of each colonoscopist prior to trial recruitment with their individual ADR in patients where EndocuffTM Vision was not used. [18 months]
Proportion of examinations expressed as a percentage where at least one adenoma is found
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18 years and over
-
Referral for screening flexible sigmoidoscopy
-
Ability to give informed consent
Exclusion Criteria:
-
Absolute contraindications to flexible sigmoidoscopy
-
Established or suspicion of large bowel obstruction or pseudo-obstruction
-
Known colon cancer or polyposis syndromes
-
Known colonic strictures
-
Known severe diverticular segment (that is likely to impede sigmoidoscope passage)
-
Patients with known active colitis (ulcerative colitis, Crohn's colitis, diverticulitis, infective colitis)
-
Patients lacking capacity to give informed consent
-
Patients who are on clopidogrel, warfarin, or other new generation anticoagulants which have not been stopped for the procedure as these will preclude polyp removal
-
Pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | South Tyneside NHS Foundation Trust | South Shields | Tyne And Wear | United Kingdom | NE34 0PL |
| 2 | Bolton NHS Foundation Trust | Bolton | United Kingdom | ||
| 3 | Gloucestershire Hospitals NHS Foundation Trust | Cheltenham | United Kingdom | GL53 7AN | |
| 4 | Dorset Healthcare University NHS Trust | Dorchester | United Kingdom | ||
| 5 | County Durham and Darlington NHS Foundation Trust | Durham | United Kingdom | DH1 5TW | |
| 6 | University Hospitals of Morecambe Bay NHS Foundation Trust | Kendal | United Kingdom | LA9 7RG | |
| 7 | Kettering General Hospital NHS Trust | Kettering | United Kingdom | NN16 8UZ | |
| 8 | North West London Hospitals NHS Trust | London | United Kingdom | HA1 3UJ | |
| 9 | Northumbria Healthcare NHS Foundation Trust | North Shields | United Kingdom | NE29 8NH | |
| 10 | Oxford Health NHS Trust | Oxford | United Kingdom | OX3 9DU | |
| 11 | Portsmouth Hospitals NHS Trust | Portsmouth | United Kingdom | PO6 3LY | |
| 12 | Pennine Acute Hospitals NHS Trust | Rochdale | United Kingdom | OL12 0NB | |
| 13 | Sheffield Teaching Hospitals NHS Foundation Trust | Sheffield | United Kingdom | S5 7AU | |
| 14 | North Tees and Hartlepool NHS Trust | Stockton on Tees | United Kingdom | TS19 8PE | |
| 15 | West Hertfordshire Hospitals NHS Trust | Watford | United Kingdom | ||
| 16 | The Royal Wolverhamptom NHS Trust | Wolverhampton | United Kingdom | WV10 0QP |
Sponsors and Collaborators
- South Tyneside and Sunderland NHS Foundation Trust
- ARC Medical Design Ltd
- Norgine
Investigators
- Principal Investigator: Colin J Rees, MBBS MRCP FRCP, South Tyneside and Sunderland NHS Foundation Trust
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- B-ADENOMA